In 2022, Bausch Health Cos. and its GI business, Salix Pharmaceuticals, filed a lawsuit against Norwich alleging that the company infringed on Bausch’s patents for the drug Xifaxan.
A U.S. District Court of Delaware decision found that some of Bausch’s drug patents were infringed and invalid, and the company is currently appealing the decision to the U.S. Court of Appeals for the Federal Circuit.
By denying Norwich’s motion, the District Court granted judgment in favor of both the FDA and Salix, according to a Nov. 1 press release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
